DE69131255T2 - Immunreaktivität gegenüber exprimierten aktivierten Oncogenen zur Diagnose und Behandlung von bösartigen Geschwülsten - Google Patents

Immunreaktivität gegenüber exprimierten aktivierten Oncogenen zur Diagnose und Behandlung von bösartigen Geschwülsten

Info

Publication number
DE69131255T2
DE69131255T2 DE69131255T DE69131255T DE69131255T2 DE 69131255 T2 DE69131255 T2 DE 69131255T2 DE 69131255 T DE69131255 T DE 69131255T DE 69131255 T DE69131255 T DE 69131255T DE 69131255 T2 DE69131255 T2 DE 69131255T2
Authority
DE
Germany
Prior art keywords
diagnosis
treatment
immunoreactivity
malignant tumors
malignancy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69131255T
Other languages
English (en)
Other versions
DE69131255D1 (de
Inventor
David J Peace
Martin A Cheever
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington Research Foundation
Original Assignee
Washington Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington Research Foundation filed Critical Washington Research Foundation
Publication of DE69131255D1 publication Critical patent/DE69131255D1/de
Application granted granted Critical
Publication of DE69131255T2 publication Critical patent/DE69131255T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464464—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
DE69131255T 1990-01-26 1991-01-24 Immunreaktivität gegenüber exprimierten aktivierten Oncogenen zur Diagnose und Behandlung von bösartigen Geschwülsten Expired - Fee Related DE69131255T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47064590A 1990-01-26 1990-01-26

Publications (2)

Publication Number Publication Date
DE69131255D1 DE69131255D1 (de) 1999-06-24
DE69131255T2 true DE69131255T2 (de) 1999-12-16

Family

ID=23868429

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69131255T Expired - Fee Related DE69131255T2 (de) 1990-01-26 1991-01-24 Immunreaktivität gegenüber exprimierten aktivierten Oncogenen zur Diagnose und Behandlung von bösartigen Geschwülsten
DE69108716T Expired - Fee Related DE69108716T2 (de) 1990-01-26 1991-01-24 Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69108716T Expired - Fee Related DE69108716T2 (de) 1990-01-26 1991-01-24 Immunreaktivität gegenüber exprimierten aktivierten oncogenen zur diagnose und behandlung von bösartigen geschwülsten.

Country Status (10)

Country Link
US (5) US5320947A (de)
EP (2) EP0617124B1 (de)
JP (3) JP2552047B2 (de)
AT (2) ATE120860T1 (de)
AU (1) AU639311B2 (de)
CA (1) CA2074720C (de)
DE (2) DE69131255T2 (de)
DK (1) DK0617124T3 (de)
ES (2) ES2070492T3 (de)
WO (1) WO1991011719A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2011099A1 (en) * 1989-04-19 1990-10-19 Stephen C. Wardlaw Determination of lymphocyte reactivity to specific antigens in blood
JP2552047B2 (ja) * 1990-01-26 1996-11-06 ワシントン リサーチ ファウンデーション 悪性腫瘍の検査方法
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
CA2118724C (en) * 1991-09-16 2002-01-15 Ulf R. Rapp Detection method for c-raf-1 genes
US5512473A (en) * 1993-01-29 1996-04-30 Brent; Roger Max-interacting proteins and related molecules and methods
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6953573B1 (en) 1993-03-17 2005-10-11 University Of Washington Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US5419900A (en) 1993-05-19 1995-05-30 The United States Of America As Represented By The Department Of Of Health And Human Services Immunologic enhancement with intermittent interleukin-2 therapy
US6156316A (en) * 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
US6942862B2 (en) * 1996-04-01 2005-09-13 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
AU5587998A (en) 1996-11-15 1998-06-03 Cornell Research Foundation Inc. Activated ras interaction assay
DE19736691A1 (de) * 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
US6551780B1 (en) * 2000-03-31 2003-04-22 The Regents Of University Of California Detection of gene mutations or amplifications in melanocytic neoplasms
AU6620300A (en) 1999-08-03 2001-02-19 Ohio State University, The Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
BR0016547A (pt) * 1999-12-22 2002-10-29 Scripps Research Inst Composição para a modulação e inibição da permeabilidade vascular (vp)
GB0007088D0 (en) * 2000-03-23 2000-05-17 Torsana A S Detection of immunological memory determining the position of loci of pathologyand therapeutic t-cell conjugates
US6772026B2 (en) 2000-04-05 2004-08-03 Therics, Inc. System and method for rapidly customizing design, manufacture and/or selection of biomedical devices
US20030119079A1 (en) * 2001-09-19 2003-06-26 The Regents Of The University Of Michigan Detection and treatment of cancers of the breast
US20040076978A1 (en) * 2001-11-14 2004-04-22 Catherine Verfaillie Method to identify genes associated with chronic myelogenous leukemia
US7794657B2 (en) * 2003-06-03 2010-09-14 Cantimer, Inc. Phase change sensor
EP2505591A1 (de) 2005-02-11 2012-10-03 Memorial Sloan-Kettering Cancer Center Verfahren und Zusammensetzungen zur Detektion eines arzneimittelresistenten EGFR-Mutanten
AU2006261342B2 (en) * 2005-06-15 2012-02-02 The Ohio State University Research Foundation Her-2 peptides
US8383799B2 (en) 2006-01-20 2013-02-26 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
EP1973946B1 (de) * 2006-01-20 2015-03-25 Cell Signaling Technology, Inc. Translokation und mutations-ros-kinase bei menschlichem nicht-kleinzelligem lungenkrebs
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
EP1994181A4 (de) * 2006-02-27 2010-05-19 Univ Arizona Identifizierung und verwendung von novopeptiden zur behandlung von krebs
US8171270B2 (en) * 2006-12-29 2012-05-01 Intel Corporation Asynchronous control transfer
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
EP3630131B1 (de) 2017-06-02 2022-08-31 Arizona Board of Regents on behalf of Arizona State University Verfahren zur erzeugung personalisierter krebsimpfstoffe für hunde

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411990A (en) * 1979-06-13 1983-10-25 University Patents, Inc. Primary bioassay of human tumor stem cells
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4643968A (en) * 1981-01-29 1987-02-17 Massachusetts Institute Of Technology Process for determining metabolism and growth of cells under various conditions
CA1219232A (en) * 1983-08-17 1987-03-17 Richard A. Lerner Polypeptide-induced monoclonal receptors to protein ligands
JPS62103573A (ja) * 1985-08-21 1987-05-14 オンコジ−ン・サイエンス・インコ−ポレ−テツド Ｒａｓがコ−ドしているタンパク質の検出用イムノアツセイ
JPH076982B2 (ja) * 1985-11-06 1995-01-30 株式会社ニチレイ 抗 体
JP2726264B2 (ja) * 1986-05-06 1998-03-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｎ‐ｍｙｃタンパク質のためのアッセイ及び抗体
US4820631A (en) * 1986-07-30 1989-04-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Deletion mutants and monoclonal antibodies against ras proteins
US4861589A (en) * 1987-03-23 1989-08-29 Trustees Of Boston University Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
US4957859A (en) * 1988-02-16 1990-09-18 Hoffmann-La Roche Inc. Antibodies for transforming ras protein
DK0474727T3 (da) * 1989-05-19 1998-01-12 Genentech Inc HER2 ekstracellulært domæne
JP2552047B2 (ja) * 1990-01-26 1996-11-06 ワシントン リサーチ ファウンデーション 悪性腫瘍の検査方法

Also Published As

Publication number Publication date
DE69131255D1 (de) 1999-06-24
DK0617124T3 (da) 1999-12-06
ES2070492T3 (es) 1995-06-01
US5601989A (en) 1997-02-11
CA2074720A1 (en) 1991-07-27
ATE180276T1 (de) 1999-06-15
EP0617124A1 (de) 1994-09-28
US20030083229A1 (en) 2003-05-01
US20040235070A1 (en) 2004-11-25
EP0513161A1 (de) 1992-11-19
CA2074720C (en) 2002-07-23
ATE120860T1 (de) 1995-04-15
EP0513161B1 (de) 1995-04-05
EP0617124B1 (de) 1999-05-19
US5773230A (en) 1998-06-30
AU639311B2 (en) 1993-07-22
JP2552047B2 (ja) 1996-11-06
DE69108716D1 (de) 1995-05-11
JPH08275774A (ja) 1996-10-22
JPH05503996A (ja) 1993-06-24
ES2134294T3 (es) 1999-10-01
AU7329991A (en) 1991-08-21
WO1991011719A1 (en) 1991-08-08
US5320947A (en) 1994-06-14
DE69108716T2 (de) 1995-08-17
JPH1169976A (ja) 1999-03-16

Similar Documents

Publication Publication Date Title
DE69131255D1 (de) Immunreaktivität gegenüber exprimierten aktivierten Oncogenen zur Diagnose und Behandlung von bösartigen Geschwülsten
DK0991421T3 (da) Påvisning og modulering af IAP'er og NAIP i forbindelse med diagnose og behandling af proliferativ sygdom
ES8704005A1 (es) Un metodo para evaluar la probabilidad de malignidad celular en una muestra biologica de un haspedante humano.
ATE535254T1 (de) Behandlung von krebs mit dem anti-erbb2- antikörper rhumab 2c4
DE60136099D1 (de) Zusammensetzungen zur behandlung und diagnose von eierstockkrebs
ATE172099T1 (de) Implantierte vorrichtung mit tumorzellen zur behandlung von krebs
EP0167616A4 (de) Cytokeratin-tumormarkierer und test zu deren nachweis.
DE3784693D1 (de) Verwendung von fluticasonpropionat zur herstellung eines praeparats zur behandlung von darmerkrankungen.
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
DE68918217D1 (de) Familie von modifizierten Antikörpern mit hoher Affinität zur Behandlung von Krebs.
DE60126495D1 (de) Nukleinsäure und protein, genannt 158p1d7, für die behandlung und erkennung von blasenkrebs und anderen krebsarten
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
YU45590A (sh) Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
DE69228824D1 (de) NACHWEISMETHODEN FÜR C-Raf-1-GENES.5
CH622922B (de) Verfahren zur herstellung von haertbaren kondensationsprodukten und deren verwendung als textilbehandlungsmittel.
ATE216266T1 (de) Einen liganden enthaltendes arzneimittel zur behandlung und/oder diagnose von weichgeweben- tumoren
DE58907851D1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
DE69110034T2 (de) Methoden und zusammensetzungen zur behandlung von bösartigen entartungen, die in zusammenhang mit einer proteinkinase stehen.
DE3577709D1 (de) Platin-intercalativ-komplexe zur behandlung von krebs.
DE59002772D1 (de) Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms.
DE69019410D1 (de) Retinoblastoma-Genprodukt-Antikörper und deren Verwendungen.
Fang et al. Subtypes of intestinal metaplasia and gastric carcinoma: A clinicoendoscopic follow-up of 112 cases
Marando et al. Complex karyotype in a case of cutaneous lymphangiosarcoma associated with chronic lymphedema of the lower limb
ATE49965T1 (de) Verwendung von 2-beta-d-ribofuranosylthiazol-4carboxamiden zur herstellung von medikamenten zur behandlung von krebsartigen tumoren.
DE69024703T2 (de) Verfahren zum Nachweis von Krankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee